Spark Therapeutics (Spark Therapeutics) LT-Debt-to-Total-Asset : 0.17 (As of Sep. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Spark Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2019 was 0.17.

Spark Therapeutics's long-term debt to total assets ratio increased from Sep. 2018 (0.06) to Sep. 2019 (0.17). It may suggest that Spark Therapeutics is progressively becoming more dependent on debt to grow their business.

Spark Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Spark Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spark Therapeutics LT-Debt-to-Total-Asset Chart

Spark Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

Spark Therapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.06	0.11	0.16	0.17

Spark Therapeutics LT-Debt-to-Total-Asset Calculation

Spark Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (A: Dec. 2018 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2018 )	/	Total Assets (A: Dec. 2018 )
	=	46.09	/	814.352
	=	0.06

Spark Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

LT Debt to Total Assets (Q: Sep. 2019 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2019 )	/	Total Assets (Q: Sep. 2019 )
	=	120.749	/	703.5
	=	0.17

Spark Therapeutics (NAS:ONCE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Spark Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Spark Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Spark Therapeutics (Spark Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104

Website

http://www.sparktx.com

Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.

Executives

Elliot Sigal	director
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster	officer: CHIEF FINANCIAL OFFICER	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga	officer: Chief Business Officer	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth	director, officer: CHIEF SCIENTIFIC OFFICER	334 CR 692, BUFFALO GAP TX 79508
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd	10 percent owner	ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High	director, officer: See Remarks	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey	officer: Chief Operating Officer	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio	officer: Chief Commercial Officer	225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju	10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025